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Abstract
HIV care and treatment settings provide an opportunity to reach people living with HIV/AIDS (PLHIV) with prevention
messages and services. Population-based surveys in sub-Saharan Africa have identified HIV risk behaviors among PLHIV, yet
data are limited regarding HIV risk behaviors of PLHIV in clinical care. This paper describes the baseline sociodemographic,
HIV transmission risk behaviors, and clinical data of a study evaluating an HIV prevention intervention package for HIV care
and treatment clinics in Africa. The study was a longitudinal group-randomized trial in 9 intervention clinics and 9
comparison clinics in Kenya, Namibia, and Tanzania (N = 3538). Baseline participants were mostly female, married, had less
than a primary education, and were relatively recently diagnosed with HIV. Fifty-two percent of participants had a partner of
negative or unknown status, 24% were not using condoms consistently, and 11% reported STI symptoms in the last 6
months. There were differences in demographic and HIV transmission risk variables by country, indicating the need to
consider local context in designing studies and using caution when generalizing findings across African countries. Baseline
data from this study indicate that participants were often engaging in HIV transmission risk behaviors, which supports the
need for prevention with PLHIV (PwP).
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Introduction
As the global HIV epidemic enters its fourth decade, 34 million
people are estimated to be living with HIV [1]. Since the
beginning of the epidemic, HIV care and treatment efforts have
rapidly expanded and 5.3 million people are now receiving anti-
retroviral treatment (ART) [2]. The expansion of HIV treatment
efforts has decreased the morbidity and mortality associated with
HIV infection and people living with HIV (PLHIV) are now living
longer [3]. Unfortunately, HIV incidence remains high with an
estimated 2.6 million new infections in 2009 [2]. Traditional HIV
prevention efforts have focused on reducing HIV risk among
individuals who are HIV-negative or of unknown serostatus.
Recently, however, there has been increasing recognition of the
importance of addressing the prevention needs of PLHIV as part
of a comprehensive and integrated HIV prevention, care, and
treatment strategy [4]. In addition, studies have demonstrated the
efficacy of providing ART as a mechanism to reduce the likelihood
of HIV transmission [5], adding further momentum to the strategy
of prevention with PLHIV (PwP).
Population-based surveys from a number of countries in sub-
Saharan Africa highlight the need for effective prevention services
for PLHIV. First, fewer than 40% of those who have HIV are
aware of their status [2], and even fewer know their partner’s HIV
status. Moreover many PLHIV, especially women, find it difficult
to disclose their HIV-positive status to their sexual partners
[6,7,8]. However, many PLHIV are in serodiscordant relation-
ships with estimates from eastern Africa indicating that 40 to 50%
of married HIV-positive individuals have an HIV-negative spouse
or partner [9,10,11]. Second, low rates of condom use in stable
relationships may place the HIV-negative partner in serodiscor-
dant partnerships at high risk of acquiring HIV [12]. Furthermore,
alcohol use among some PLHIV has been found to be high and is
associated with both increased risky sexual behavior [13,14] and
reduced adherence to antiretroviral medications (ARVs) [15].
PLHIV may also be co-infected with other sexually transmitted
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infections (STIs) which can be more severe and difficult to treat in
HIV-positive persons, and incident STIs are an indicator of
unprotected sex [16]. Another effective prevention service is
preventing mother to child transmission (PMTCT) of HIV.
Although PMTCT services are improving in sub-Saharan Africa,
many HIV-positive women report an unmet need for contracep-
tion and safer pregnancy counseling [12,17], and with access to
PMTCT services often limited, access to contraception is even
more critical.
Many PLHIV in these population studies are not aware of their
status and may not be enrolled in HIV clinical care [10,12,13].
However, with the expansion of HIV care and treatment services,
more PLHIV are now engaged in clinical care and have regular
contact with health care providers. Yet data are limited regarding
whether PLHIV in care are engaging in behaviors that put them at
risk for acquiring other STIs or transmitting HIV to uninfected
partners. In addition, studies that have been done among PLHIV
in clinical settings have typically been small scale and conducted in
a single country. This paper describes the baseline socioedemo-
graphic, HIV risk behaviors, and clinical data for a clinic-based
HIV prevention intervention for PLHIV attending HIV care and
treatment clinics in Kenya, Namibia, and Tanzania. Country
differences in health and risk behaviors are also examined in order
to explore how these factors differ across cultural contexts.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design
The study was a longitudinal group-randomized trial, random-
ized at the clinic level. Six HIV care and treatment clinics in each
of three countries (Kenya, Namibia, and Tanzania) participated,
for a total of 18 clinics. The sites chosen were six district-level
hospitals with HIV outpatient facilities on-site. Each clinic was
matched to another clinic in the same country based on level of
care and services provided (e.g., health care provider/patient ratio,
number of HIV-positive patients enrolled in care), for a total of
three pairs of clinics in each country. Intervention status was
randomly assigned (by coin flip) to one clinic in each of the three
matched pairs. The other clinic was assigned to a wait-list
comparison condition. At the intervention clinics, health care
providers (HCPs) and lay counselors (LCs) were trained to provide
a package of HIV prevention messages and services (described
below) as part of the routine care offered to all HIV-positive
patients (not just study participants) during their clinic visits. In the
comparison clinics, providers and staff delivered services following
their usual standard of care. Following final study data collection,
HCPs and LCs in the comparison clinics were trained to deliver
the HIV prevention services and messages.
Patient participants were assessed at baseline, 6-months, and 12-
months post-intervention. To allow sufficient time for patients to
be exposed to the intervention during regular clinic visits, the 6-
month follow-up data collection began 6 months after clinic staff
were trained and the intervention was implemented. To make the
intervention and comparison clinic project procedures as similar as
possible, the 6 and 12-month follow-up assessments occurred
during the same time periods in both the intervention and
comparison clinics.
HIV Prevention Intervention. The intervention and mate-
rials developed for this project were adapted from Partnership for
Health (PfH) [18], which is a brief, provider-delivered counseling
program for PLHIV. PfH is designed to improve patient-provider
communication about safer sex, disclosure of serostatus, and HIV
prevention by incorporating counseling about safer sex and
disclosure into the routine services provided to all PLHIV by
health care providers during each clinic visit. It is based on a social
cognitive model that uses message framing, repetition, and
reinforcement to increase the patient’s knowledge, skills, and
motivations to practice safer sex. The investigators obtained input
from health care providers in Kenya, Uganda, and Botswana for
the adaptation of the materials for the African context and field
tested the interventions in clinics in Kenya. The original
intervention was expanded to include additional prevention
messages (e.g., partner testing, alcohol reduction) and services
(e.g., family planning, STI screening) to more comprehensively
address prevention with PLHIV within the context of sub-Saharan
Africa.
Following completion of the baseline data collection, HCPs
(including physicians, clinical officers, nurses, pharmacists) in the
intervention clinics were trained to incorporate HIV prevention
services and messages into their routine clinical patient assessments
and to provide these services and messages to all clinic patients
(not just study participants) during each routine clinic visit.
Specifically, when HCPs met with a patient individually in the
exam room they incorporated HIV prevention services and
messages into the routine care provided to the patients. The HIV
prevention services included assessing and addressing sexual risk
behaviors, partner HIV testing and knowledge of partner’s status,
medication adherence, alcohol use; identifying and treating STIs;
and providing sufficient quantities of condoms. HCPs also
addressed family planning needs. For those desiring pregnancy,
guidance on safer conception, pregnancy, and delivery was
provided to men and women. Participants who did not currently
desire pregnancy were encouraged to use condoms plus another
form of highly effective contraception. Hormonal contraceptives
were provided within the HIV care and treatment clinics and
women who were interested in long-acting methods were referred
to other clinics to receive those methods. Health care providers
were also trained to help patients set a prevention goal (e.g.,
increasing condom use).
Trained lay counselors provided group education sessions in
clinic waiting areas on basic HIV/AIDS, HIV transmission to
partners, mother-to-child transmission, treatment adherence, and
healthy living. In addition, they provided individual counseling on
the prevention issues raised by HCPs including disclosure,
encouraging HIV testing of sex partner(s) and children, condom
use (including condom use demonstrations), alcohol reduction, and
medication adherence. Finally, counselors were trained to conduct
partner and couples HIV testing and counseling (Namibia and
Kenya). In Tanzania, lay counselors only provided pre- and post-
test counseling, as they were not permitted by national guidelines
to conduct HIV testing. Patients were either referred by HCPs to
the LCs for additional counseling or the patients could choose on
their own to visit the LCs.
Ethics. The study was reviewed and approved by Institutional
Review Boards (IRBs) at all the collaborating institutions
conducting the research. These included the US Centers for
Disease Control and Prevention (CDC), Columbia University
Medical Center, Kenya Medical Research Institute (KEMRI)/
National Ethical Review Committee, Namibia Ministry of Health
and Social Services (MOHSS), Tanzania National Institute of
Medical Research (NIMR), and Zanzibar Medical Ethical
Committee (ZAMEC).
Eligible participants were read an informed consent form and
given the opportunity to ask questions before written consent was
Prevention with PLHIV in Clinic Settings
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obtained. Participants consented to complete three questionnaires
during the study period, allow collection of information from their
medical charts, and provide contact information for participant
tracking during the follow-up period. Participants were offered a
drink and/or a small snack during or after the questionnaire
administration.
Data collection procedures
Each day, study staff approached every third patient in the
clinic waiting area and asked if he/she was interested in
participating in a study. Interested patients were taken to a private
area, told about the project, and screened for eligibility. Inclusion
criteria required that patient participants were 18 years of age or
older, enrolled in the HIV care and treatment clinic (documented
HIV infection) and had received care at the study clinic at least
twice prior to study enrollment. Participants also had to report
being sexually active within the past 3 months, and report
planning to attend the clinic for at least 1 year. Women who knew
they were pregnant and male partners of pregnant women were
ineligible for study enrollment, as family planning counseling and
pregnancy were study outcomes. Respondents who were aware of
their partners already participating in the study were excluded. All
patient interviews were available in English, as well as Kiswahili (in
Kenya and Tanzania) and Oshiwambo and Afrikaans (in
Namibia).
In order to have sufficient representation of patient participants
by gender and ART status, each clinic attempted to enroll equal
numbers of men and women, as well as equal numbers of ART
and pre-ART patients (care only). Treatment status was assessed
on the screening form to track the number of participants enrolled
in each group.
The patient baseline questionnaire took approximately one
hour to complete and was administered by a trained project
interviewer who was not part of the clinic staff. Data collection
start dates were staggered across countries, with each baseline data
collection period taking approximately 3 months. Baseline data
collection began in October 2009 and was completed in all
countries by April 2010. Data presented in this paper were
collected from patient medical chart review and patient question-
naires.
Medical Chart Review. Data extracted from patients’
medical charts included date of HIV diagnosis, dates of HIV
clinic visits in the past 6 months, clinical indicators of HIV (e.g.,
most recent CD4 count, WHO clinical stage), prescribed
medications, pregnancy status, contraceptive use, STI symptoms
and STI treatment provided, and meetings with lay counselors. In
addition, data on dates and amount of medication dispensed to
patients in the past 6 months were collected from pharmacy
records.
Participant Questionnaire. The patient questionnaire col-
lected information regarding sociodemographics, HIV testing and
care, mental and physical health, social support, alcohol use, HIV
medications and adherence, disclosure of serostatus, knowledge of
HIV/AIDS, sexual behavior, sexual self-efficacy, history of
violence, STIs, fertility desire, family planning, and prevention
services received. As much as possible, measures included in the
questionnaire had been used previously in studies conducted in
Africa.
To assess adherence participants were asked to name their HIV
medications, number of pills taken, dose (number of times per
day), and whether they had missed any doses in the last 30 days
[19,20]. For sexual behavior, participants could report up to five
partners with whom they had sex in the past 3 months and
identified whether each partner was a spouse, main partner, or
non-main partner. Disclosure of the participant’s HIV status to
each sex partner(s) was assessed. For this analysis, disclosure of
HIV status was to their spouse or most recent main partner. If they
didn’t report a spouse or main partner, disclosure to a non-main
partner was used. Participants also indicated whether each partner
had been tested for HIV and if so, whether the participant knew
that partner’s HIV status.
The 10-item World Health Organization’s Alcohol Use
Disorders Identification Test (AUDIT) [21] was used to measure
alcohol use. Based on the AUDIT scoring criteria, participants
were categorized as non-drinker (0), non-problem drinker (,8),
problem drinker ($8), and likely dependent on alcohol ($13 for
women, $15 for men). STI symptoms were based on patients’
report of whether they had experienced discharge from the penis
or vagina, sores in the genital area, or (for female patients only)
abdominal pain.
Data analysis
The SAS GLIMMIX procedure was used to test for differences
between countries (Table 1) and between males and females for
categorical variables (SAS PROC MIXED was used for contin-
uous variables). When testing for country differences, clinic was
entered as a random effect to account for the correlation of
observations within clinic, country was entered as a categorical
independent variable, and the variable of interest was entered as
the dependent variable. A multinomial distribution with a
generalized logit link was assumed for the dependent variable.
For gender differences, gender was the independent variable and
the variable of interest was the dependent variable. Clinic was
again entered as a random effect and the appropriate distribution
for the dependent variable used (binomial, multinomial or
continuous). All data analyses were considered significant at
p,0.05.
Results
Participants
A total of 3,538 eligible patient participants were enrolled and
completed the baseline questionnaire between September 2009
and April 2010 (see Figure 1 for patient flow diagram). Despite
intensive recruitment efforts, all countries had difficulty enrolling
male patients, especially those who were receiving care only and
not taking ARVs. Given the challenges enrolling men, the
recruitment goals for each clinic were revised from an even 50
participants in the male/female and on ARV/not on ARV groups
to 60 males and 60 females on ARVs, 50 females in care only, and
30 men in care only. Even with these revised targets, one clinic
had difficulty recruiting men who were in care only.
Sociodemographics
The majority of participants (58%) were female (Table 1).
Nearly half of participants were between 30 and 39 years old;
however, women were younger (M = 35, SD = 7) compared to
men (M = 41, SD = 9, F = 548, p,.0001). Nearly two-thirds of
participants either attended school through the primary grades
(54%) or had not attended school (10%). Sixty one percent of study
participants reported being married or living together as married.
More men (69%) than women (56%) reported being married/
living together as married (F = 29.55, p,0.0001). Only 5% of
married men reported 2 wives or partners they lived with as
married, although 13% of married women reported that their
husband had more than 1 wife or partner that he lived with as
married. Ninety percent of participants had children who were still
Prevention with PLHIV in Clinic Settings
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Table 1. Sociodemographic and health characteristics of baseline PwP evaluation study participants.
Overall
(n = 3538)
Kenya
(n = 1156)
Namibia
(n = 1186)
Tanzania
(n = 1196)
Country
Differences*
n (%) n (%) n (%) n (%) p-value
Gender 0.5139
Male 1483 (41.9) 490 (42.4) 514 (43.4) 479 (40.1)
Female 2054 (58.1) 665 (57.6) 672 (56.7) 717 (60.0)
Age 0.0045
18–29 616 (17.4) 229 (19.8) 215 (18.1) 172 (14.4)
30–39 1667 (47.1) 545 (47.2) 585 (49.3) 537 (44.9)
40–49 980 (27.7) 303 (26.2) 306 (25.8) 371 (31.0)
$50 274 (7.8) 78 (6.8) 80 (6.8) 116 (9.7)
Education ,0.0001
No school 340 (9.6) 27 (2.3) 95 (8.0) 218 (18.3)
Primary 1890 (53.5) 665 (57.6) 403 (34.0) 822 (69.0)
Secondary 1214 (34.4) 394 (34.1) 678 (57.2) 142 (11.9)
More than secondary 88 (2.5) 69 (6.0) 9 (0.8) 10 (0.8)
Marital status ,0.0001
Married/living together 2170 (61.4) 822 (71.2) 542 (45.7) 806 (67.5)
Single, never married 781 (22.1) 95 (8.2) 608 (51.3) 78 (6.5)
Separated/divorced 359 (10.2) 156 (13.5) 10 (0.8) 193 (16.2)
Widowed 225 (6.4) 82 (7.1) 26 (2.2) 117 (9.8)
Number of wives (married/cohabiting males only) 0.2266
1 972 (94.8) 381 (97.0) 271 (93.5) 320 (93.6)
2 53 (5.2) 12 (3.1) 19 (6.6) 22 (6.4)
Number of wives/partners husband lives with (married
females only)
0.1064
1 943 (86.8) 389 (91.8) 187 (87.0) 367 (81.9)
2 123 (11.3) 31 (7.3) 21 (9.8) 71 (15.9)
3–5 21 (1.9) 4 (0.9) 7 (3.3) 10 (2.2)
Number of people in household ,0.0001
1–2 719 (20.4) 313 (27.1) 193 (16.4) 213 (17.9)
3–4 1218 (34.6) 513 (44.5) 312 (26.5) 393 (33.0)
5–6 826 (23.4) 258 (22.4) 244 (20.7) 324 (27.2)
$7 761 (21.6) 70 (6.1) 429 (36.4) 262 (22.0)
Have children (% yes) 3196 (90.4) 1084 (93.9) 1059 (89.3) 1053 (88.0) ,0.0001
Number of living children (of those with children) 0.0218
0–1 762 (23.9) 268 (24.7) 254 (24.1) 240 (22.8)
2 868 (27.2) 327 (30.2) 283 (26.8) 258 (24.5)
3 659 (20.6) 234 (21.6) 209 (19.8) 216 (20.5)
$4 904 (28.3) 255 (23.5) 310 (29.4) 339 (32.2)
Religion ,0.0001
Roman Catholic 728 (20.6) 311 (27.0) 236 (19.9) 181 (15.1)
Evangelical/Pentecostal 954 (27.0) 251 (21.8) 670 (56.6) 33 (2.8)
Islamic/Muslim 912 (25.8) 9 (0.8) 0 (0.0) 903 (75.5)
Protestant 477 (13.5) 428 (37.1) 7 (0.6) 42 (3.5)
Other 463 (13.1) 155 (13.4) 271 (22.9) 37 (3.1)
Paid work last 6 mos. (% yes) 1565 (44.3) 744 (64.4) 555 (46.9) 266 (22.3) ,0.0001
Paid work last 7 days (% yes, of those who worked in past
6 mos.)
1307 (83.3) 651 (87.5) 452 (81.2) 204 (76.1) 0.0589
Monthly household incomeb 0.0079
,30 USD 929 (30.8) 225 (20.6) 301 (27.6) 403 (48.4)
Prevention with PLHIV in Clinic Settings
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living and 51% had 2 or fewer living children. There were country
differences in sociodemographics which are shown in Table 1.
Because there were no Islamic/Muslim participants in Namibia,
one Muslim observation was added per site in Namibia (6 total) to
allow the model to converge. There were significant differences in
religion (F = 52.03, p,0.0001; Table 1). Tanzania had 75%
Islamic/Muslim participants, whereas Kenya was more evenly
split among the different religions, with the largest group being
Protestant (37%). Namibian participants were mostly Evangelical/
Pentecostal (56%).
Less than half of participants (44%) had done paid work in the
last 6 months. Among those who had worked in the last 6 months,
83% had also worked in the past 7 days. Men were more likely to
have reported paid work in the last 6 months (55%) than women
(37%; F = 126.24, p,0.0001) and in the last 7 days (male = 86%,
female = 81%; F = 5.31, p = 0.02). Monthly household income was
converted from local currency to US dollars for comparability
across countries, with 68% of participants earning less than $100
per month.
Health Status and Medication Adherence
About a quarter (26%) of participants were diagnosed with HIV
in the previous year, and more than two-thirds (70%) had been
diagnosed with HIV within the past 3 years. In Namibia, nearly
Table 1. Cont.
Overall
(n = 3538)
Kenya
(n = 1156)
Namibia
(n = 1186)
Tanzania
(n = 1196)
Country
Differences*
n (%) n (%) n (%) n (%) p-value
30–99 1131 (37.5) 524 (48.0) 328 (30.1) 279 (33.5)
$100 954 (31.7) 344 (31.5) 460 (42.2) 150 (18.0)
Years since HIV diagnosis ,0.0001
,1 years 925 (26.2) 331 (28.7) 189 (16.0) 405 (33.9
1 to ,2 years 806 (22.8) 283 (24.5) 200 (16.9) 323 (27.0)
2 to ,3 years 723 (20.5) 250 (21.7) 218 (18.4) 255 (21.3)
$3 years 1081 (30.6) 291 (25.2) 577 (48.7) 213 (17.8)
Most recent CD4 0.4564
,200 828 (23.7) 245 (21.3) 304 (26.1) 279 (23.6)
200–349 1036 (29.6) 338 (29.3) 341 (29.3) 357 (30.2)
350–500 797 (22.8) 278 (24.1) 269 (23.1) 250 (21.2)
$501 838 (24.0) 291 (25.3) 252 (21.6) 295 (25.0)
Notes. Percentages may not total to 100% due to rounding. The number of participants for individual variables may not sum to overall totals due to non-response from
some participants.
*F-statistics used to test for country differences.
aOne Muslim observation was added per site in Namibia (6 total) to allow the model to converge.
bLocal currency was converted to US dollars (USD) for comparability.
doi:10.1371/journal.pone.0057215.t001
Figure 1. Flow diagram of patient participants in a group-randomized trial of prevention with people living with HIV in HIV care
and treatment clinics.
doi:10.1371/journal.pone.0057215.g001
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half of participants had been diagnosed for over 3 years, compared
with only 25% of Kenyan and 18% of Tanzanian participants
(p,0.0001). Nearly a quarter of all participant’s most recent CD4
count was less than 200 cells/mm3, and another 30% had CD4
counts between 200 and 349. ART patients had a median CD4
count of 287 cells/mm3 (median time since CD4 test = 137 days)
and the median CD4 count for those not on ART was 413
(median time since test = 83 days). Among participants who had
been on ARVs less than one year, the median CD4 was 190 cells/
mm3. Although there were no significant gender differences in
time since HIV diagnosis, CD4 count was significantly higher for
women compared to men (422 vs. 332, p,0.0001).
Nearly all participants (88%) were taking HIV medications
(ARVs and cotrimoxazole), and 83% of those taking medications
reported that they had not missed any doses in the last 30 days
(Table 2). There was no significant difference in adherence
between those taking cotrimoxazole only compared with those on
both ARVs and cotrimoxazole. When limited to the 64% of
Table 2. Participant baseline HIV risk behaviors by country.
Overall
(n = 3538)
Kenya
(n = 1156)
Namibia
(n = 1186)
Tanzania
(n = 1196)
Country
Differences*
n (%) n (%) n (%) n (%) p-value
Disclosed HIV status to partner 0.99
No 640 (18.2) 216 (18.7) 120 (10.2) 304 (25.5)
Yes 2879 (81.8) 937 (81.3) 1053 (89.8) 889 (74.5)
Partner’s HIV status ,0.0001
HIV+ 1675 (47.6) 548 (47.5) 681 (58.3) 446 (37.3)
HIV2 666 (18.9) 217 (18.8) 179 (15.3) 270 (22.6)
Unknown 1177 (33.5) 389 (33.7) 309 (26.4) 479 (40.1)
Consistent condom use, past 3 monthsa ,0.0001
No 765 (23.7) 269 (24.2) 137 (14.2) 359 (31.1)
Yes 2466 (76.3) 842 (75.8) 828 (85.8) 796 (68.9)
Alcohol use (AUDIT) ,0.0001
Non-drinker 2826 (80.1) 985 (85.4) 813 (69.0) 1028 (86.0)
Non-problem drinker 518 (14.7) 101 (8.8) 275 (23.3) 142 (11.9)
Harmful drinker 113 (3.2) 34 (3.0) 61 (5.2) 18 (1.5)
Likely dependent 71 (2.0) 34 (3.0) 29 (2.5) 8 (0.7)
Taking HIV medicationsb ,0.0001
No 420 (11.9) 2 (0.2) 351 (29.6) 67 (5.6)
Yes 3116 (88.1) 1153 (99.8) 835 (70.4) 1128 (94.4)
Missed dose of HIV medication,b past 30 days 0.71
No 2574 (82.6) 975 (84.6) 686 (82.2) 913 (80.9)
Yes 542 (17.4) 178 (15.4) 149 (17.8) 215 (19.1)
Any STI symptoms, ever 0.005
No 2258 (63.8) 605 (52.4) 800 (67.5) 853 (71.3)
Yes 1279 (36.2) 550 (47.6) 386 (32.6) 343 (28.7)
Any STI symptoms, past 6 months 0.88
No 3135 (88.7) 1013 (87.7) 1062 (89.7) 1060 (88.8)
Yes 398 (11.3) 142 (12.3) 122 (10.3) 134 (11.2)
Desire pregnancy or partner pregnancy in next 6
months
,0.0001
No 2870 (83.5) 998 (88.9) 960 (82.9) 912 (78.9)
Yes 567 (16.5) 125 (11.1) 198 (17.1) 244 (21.1)
Use highly effective family planning methodc 0.04
No 1837 (65.0) 605 (60.8) 550 (59.5) 682 (75.1)
Yes 991 (35.0) 390 (39.2) 375 (40.5) 226 (24.9)
Notes. Percentages may not total to 100% due to rounding. The number of participants for individual variables may not sum to overall totals due to non-response from
some participants.
*F-statistics used to test for country differences.
aUsed a condom at every sexual encounter.
bIncludes antiretroviral medications and cotrimoxazole.
cAmong those not desiring pregnancy or partner pregnancy (males). Family planning methods include pill, injectable, IUD, implant, male and female sterilization.
doi:10.1371/journal.pone.0057215.t002
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participants taking ARVs, adherence rates were similar with 81%
reporting that they had not missed a dose in the past 30 days.
HIV Transmission Risk Behaviors
Most participants (82%) reported that they had disclosed their
HIV status to their partner (Table 2). Two-thirds of participants
reported that they knew their partner’s HIV status, with 48%
reporting their partner was HIV-positive, 19% reporting their
partner was HIV-negative, and 34% of participants did not know
their partner’s HIV status.
Self-reported consistent condom use rates were high with 76%
of participants reporting that they had used a condom at every
sexual encounter in the past three months (Table 2). Men were
more likely to report consistent condom use than women (81% vs.
73%, p,0.0001). There were also country differences (p,0.0001),
with more participants in Namibia reporting consistent condom
use (86%) compared with Kenya (76%) and Tanzania (69%).
Most participants (80%) reported no alcohol use, 15% were
non-problem drinkers, 3% harmful drinkers, and 2% scored as
likely dependent on alcohol (Table 2). Fewer men reported no
alcohol use and they were more likely than women to be classified
as non-problem or harmful drinkers. There were also significant
country differences (p,0.0001).
Over one-third of participants (36%) reported ever experiencing
STI symptoms (Table 2), with significant country differences
(p = 0.005), but no significant gender differences. Eleven percent of
participants reported STI symptoms in the past six months, with
more women (14%) reporting symptoms than men (7%; F = 46.52,
p,.0001).
Female participants were asked whether they desired a
pregnancy and male participants were asked whether they desired
their spouse or main partner to be pregnant in the next 6 months.
Only 17% of participants desired pregnancy (Table 2), although
more men reported desiring their partners to be pregnant (20%)
than women reported desiring a pregnancy (14%; p,.0001).
There were also country differences, with Tanzanian participants
more likely to desire pregnancy (21%), followed by 17% of
Namibians and 11% of Kenyan participants (p,.0001).
Among female participants who did not desire pregnancy and
males who did not desire their partner to be pregnant, only 35%
were using a highly effective contraceptive method (e.g., pills,
injectable, IUD, implant, male or female sterilization). There were
significant country differences in highly effective contraceptive use
(p = .04); participants in Tanzania reported lower rates of
contraceptive use (25%) than participants in either Kenya (39%)
or Namibia (41%).
Discussion
The group-randomized trial described in this paper is designed
to evaluate the effectiveness and feasibility of integrating HIV
prevention into the routine care of PLHIV attending care and
treatment clinics in Kenya, Namibia, and Tanzania. Baseline data
from the study participants provides information about the
sociodemographic characteristics, health status, and HIV risk
behavior of patients attending care. These data indicate that
participants were similar in socioeconomic status (SES) to
nationally representative samples in each of the countries
[10,22,23], with low education and income levels. The lack of
paid work and low income reported by many of the PLHIV in this
study may affect their health and clinic attendance. For example,
transportation costs are often reported as a reason for poor clinic
attendance among PLHIV [24,25,26].
The mean age of participants in this sample was higher than
national estimates of ages of PLHIV, especially for women
[10,22,23,27]. In addition, the majority of participants in this
study were diagnosed with HIV within the past 3 years. Over half
of participants had their most recent CD4 count less than 350
cells/mm3, and participants who had been on ARVs less than one
year (20% of those on ARVs) had very low CD4 counts
(median = 170). These data suggest that many participants
accessed care late in their illness, a finding consistent with other
studies from sub-Saharan Africa showing that many patients
access care after developing advanced symptomatic disease
[28,29,30,31] and aren’t benefiting from care and treatment
interventions to improve morbidity and mortality. In addition,
their declining CD4 counts and increased viral load are also
placing their sexual partners at increased risk of HIV acquisition
[32,33,34,35,36]. Increased HIV testing and counseling (HTC)
efforts with focused linkage to care and treatment services in both
facilities (e.g., ANC, TB, STI, and out-patient departments) and
communities (e.g., home-based testing and mobile testing) are
needed to identify individuals with asymptomatic disease, espe-
cially men, and ensure earlier enrollment into appropriate
prevention, care, and treatment services. In addition, as one-third
of participants did not know their partners’ HIV status, more
intensive efforts are clearly needed to increase partner and couple
testing to identify HIV-positive persons and discordant couples
and to link them with prevention, care, and treatment services.
Men in HIV care and treatment clinics and in the study sample
are under-represented compared to the population of PLHIV.
Men also had significantly lower CD4 counts than women. Nearly
two-thirds of men had CD4 counts less than 350 cells/mm3
compared to less than half of women (64% vs. 46%, p,0.0001).
This is consistent with several other studies from sub-Saharan
Africa which have found that men are less likely than women to
enroll in care at an earlier clinical stage [37,38,39], and to remain
in clinical care after enrollment [40,41,42]. These findings
highlight the importance of strengthening HIV testing and
counseling programs targeting men, such as medical male
circumcision programs and partner testing in ANC settings.
Efforts to identify HIV-positive men earlier, link them to
prevention, care and treatment services, and retain them in care
are clearly needed.
The risk behavior data from this study identify HIV prevention
needs among PLHIV attending HIV clinics. Specifically, nearly
one-fifth of the participants were in a known discordant
relationship, and over one-third did not know their partner’s
HIV status. In addition, 18% of the sample had not disclosed their
HIV status to their partner and 24% were not consistently using
condoms. These data indicate that many participants are in need
of prevention services such as support for disclosure of HIV status,
partner testing, and reducing unprotected sex. In addition, alcohol
use was reported by about 20% of participants. Alcohol use has
been associated with poor adherence [43,44,45] and increased
disease progression [46,47,48], as well as increased risky sexual
behavior among PLHIV [49]. Interventions to address these
prevention issues in the context of comprehensive care and
treatment services are indicated.
There were significant differences between countries in many of
the reported HIV risk behaviors. For example, consistent condom
use among PLHIV in care was 86% in Namibia, but significantly
lower in Tanzania (69%). Similarly, only 60% of participants in
Tanzania and 63% in Kenya knew their partner’s HIV status, but
73% of Namibian participants knew their partner’s status. There
were differences in reported alcohol use as well, with Tanzanian
and Kenyan participants less likely to drink alcohol than Namibian
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participants, and Tanzanian participants also less likely to report
problem drinking. These participant baseline differences between
countries highlight the importance of considering the local context
when designing multi-country studies and the need to recognize
that regional differences could affect generalizability of results
from studies conducted in a single region or country.
This study has several limitations. Given that this was a clinic-
based sample conducted in three countries with generalized HIV
epidemics, the generalizability of these findings to PLHIV not
enrolled in clinical care and/or to PLHIV in non-generalized
epidemics may be limited. In addition, much of the data in this
paper are from patient self-report, thus social desirability and
recall bias may have affected participants’ responses. As a result,
some variables may be overestimated (e.g., condom use, disclosure,
adherence) and others underestimated (e.g., alcohol use).
In summary, the baseline data from this study suggest that
increased efforts are needed to identify PLHIV earlier, especially
men, and to ensure they access prevention, care, and treatment
services following diagnosis. Many PLHIV would also benefit from
prevention interventions which address disclosure support, partner
testing, alcohol and sexual risk reduction, as well as providing
contraceptives and support for safer pregnancy. Integrating these
services into the clinical care of HIV-positive persons may increase
access to prevention interventions and improve retention in
clinical care [4].
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